Cyclopharm has secured regulatory approval for Technegas in Colombia, marking the 67th country where the functional lung imaging technology is now cleared for clinical use. The Cyclopharm Technegas Colombia approval comes ahead of the World Federation of Nuclear Medicine and Biology (WFNMB) Congress in Cartagena, Colombia, scheduled for February 2026, providing strategic timing for market engagement and education.
Cyclopharm Secures Colombia Approval for Technegas – 67th Country Milestone
The Colombia regulatory win extends Cyclopharm’s global footprint in functional lung imaging, where Technegas enables clinicians to directly visualise where oxygen is delivered within the lungs. This approval supports the company’s strategy of expanding access to true functional imaging, particularly as artificial intelligence (AI) platforms enhance the technology’s clinical utility. The 67-country milestone reflects sustained momentum in regulatory approvals across diverse healthcare markets.
The timing aligns with the WFNMB Congress in Cartagena in early February 2026, a major international forum where nuclear medicine professionals, researchers, and industry leaders will converge. This creates an immediate promotional platform for Cyclopharm to showcase advances in AI-enabled functional lung imaging and engage key opinion leaders across Latin America.
For investors, the approval validates the replicability of Cyclopharm’s market entry strategy and positions the company to leverage a concentrated educational opportunity at a global congress occurring in the newly approved market.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
What Does Technegas Approval in Colombia Mean for Cyclopharm?
Colombia represents a growth market entry point for Latin America, where Cyclopharm will work with local partners and clinical centres to support education and adoption following regulatory clearance. The company’s partnership model has proven effective in multiple jurisdictions, enabling market access without requiring direct infrastructure investment.
The commercialisation pathway follows a three-step sequence:
- Regulatory Approval – Clearance to market and sell Technegas in Colombia
- Clinical Education – Training programmes with local partners and key centres to build clinical familiarity
- Adoption and Revenue – Recurring sales from Technegas generators (devices) and consumables as procedures scale
The WFNMB Congress provides accelerated access to this pathway. Hosting the global nuclear medicine community in Cartagena creates concentrated engagement with regional decision-makers, potential distribution partners, and clinical champions who can drive adoption across Latin American markets.
For investors, this validates the scalability of Cyclopharm’s market entry playbook and demonstrates how strategic timing can create promotional leverage, potentially compressing the education-to-adoption timeline compared to markets without such catalysts.
Understanding Functional Lung Imaging: Why Technegas Matters
Functional lung imaging visualises how the lungs actually perform, rather than just their physical structure. Traditional CT scans show anatomical detail (what the lungs look like) but provide limited information about regional lung function (how well different areas are working). Technegas addresses this gap by enabling clinicians to see where oxygen is delivered at the site of gas exchange.
The technology provides high-resolution ventilation imaging with a radiation dose orders of magnitude lower than diagnostic CT imaging. This safety profile supports repeat imaging in vulnerable patient populations, including children and those requiring longitudinal monitoring for chronic respiratory conditions. Lower radiation exposure also enables more frequent functional assessments during treatment planning and post-intervention follow-up.
Technegas is supported by hundreds of peer-reviewed publications and millions of patient procedures performed globally. It is included by name in internationally endorsed clinical guidelines for pulmonary embolism diagnosis, reflecting established clinical validation.
Managing Director Commentary
“The approval of Technegas in Colombia is particularly timely, with the World Federation of Nuclear Medicine and Biology (WFNMB) Congress scheduled to be held in Cartagena, Colombia, in early February 2026. The WFNMB Congress represents a major global forum at which the international nuclear medicine community will converge, providing an important opportunity to showcase advances in AI enabled functional lung imaging and to engage with leading clinicians and researchers, along with industry leaders, from around the world,” said James McBrayer, Managing Director.
For investors, clinical differentiation translates to pricing power and sticky adoption. The safety profile expands addressable patient populations beyond pulmonary embolism into chronic disease monitoring and intervention planning.
How Is AI Expanding Technegas Use in Lung Imaging?
AI-enabled post-processing and analytics are accelerating the expansion of Technegas beyond pulmonary embolism into broader respiratory applications. These include COPD, asthma, lung transplantation, and functional lung mapping for surgical and radiotherapy planning. AI platforms enhance quantification of ventilation patterns, enabling more precise and personalised evaluation of regional lung function.
This integration positions Technegas as a platform technology rather than a single-indication diagnostic tool. Better quantification supports more personalised treatment planning, which in turn drives more use cases across respiratory medicine and interventional applications. Cyclopharm is effectively riding two healthcare transformation waves: the shift toward functional imaging and the adoption of AI in medical diagnostics.
| Traditional Primary Use | Emerging Respiratory Applications | AI Enhancement Capabilities |
|---|---|---|
| Pulmonary Embolism Diagnosis | COPD, Asthma, Lung Transplant Monitoring | Quantification of Ventilation Patterns |
| Established Guideline Inclusion | Surgical Planning (Lobectomies, Lung Volume Reduction) | Personalised Functional Evaluation |
| Single Diagnostic Assessment | Radiotherapy Planning and Functional Mapping | Enhanced Regional Lung Function Analysis |
For investors, AI integration significantly expands the total addressable market. Next-generation imaging centres adopting AI workflows are more likely to integrate Technegas as a standard tool, creating stickiness and recurring revenue visibility as the technology becomes embedded in clinical protocols across multiple specialties.
Clinical Evidence and Guideline Recognition
Technegas benefits from established clinical credibility, with inclusion by name in internationally endorsed guidelines for pulmonary embolism diagnosis. This guideline recognition positions the technology as a de facto standard of care in its primary indication.
The evidence base is supported by hundreds of peer-reviewed journal publications and millions of patient procedures performed globally. This clinical validation reduces regulatory and reimbursement risk in new markets, as health authorities and payers can reference an extensive body of real-world data when evaluating coverage decisions.
For investors, guideline inclusion provides competitive moat advantages and de-risks market entry strategies in newly approved jurisdictions like Colombia.
Why Is Technegas Approved in 67 Countries Worldwide?
The 67-country footprint reflects proof of concept for Cyclopharm’s regulatory strategy and demonstrates product-market fit across diverse healthcare systems. The approval-partnership-adoption model has proven repeatable, with regulatory success in major markets validating the clinical and commercial proposition.
This installed base creates network effects. More procedures generate more clinical data, leading to more publications, which in turn facilitate easier approvals in remaining markets. Regulatory momentum compounds as evidence accumulates.
Key approved regions and markets include:
- United States (FDA clearance)
- European Union (widespread adoption)
- Japan (established market presence)
- Australia (home market)
- Colombia (latest approval, 67th country)
For investors, the large installed base provides recurring revenue visibility through the consumables model (Technetium-99m doses required for each procedure). Scale advantages in manufacturing and distribution improve unit economics as the company expands into additional markets. Regulatory momentum de-risks future approval timelines.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
What’s Next for Cyclopharm?
The immediate focus centres on the WFNMB Congress in Cartagena in February 2026, where Cyclopharm will engage the international nuclear medicine community and showcase AI-enabled functional lung imaging advances. Concurrently, the company will collaborate with local partners in Colombia to activate the market through education programmes and clinical centre engagement.
Broader strategic priorities include continued expansion of AI-enabled applications across respiratory medicine and pursuit of additional country approvals. The company is positioned to capitalise on two structural trends: growing adoption of functional imaging in clinical workflows and integration of AI analytics platforms in radiology and nuclear medicine departments.
For investors, near-term catalysts include congress outcomes and Colombia market activation milestones. The long-term investment thesis remains intact: expanding clinical indications combined with geographic reach create compounding revenue growth potential as Technegas becomes embedded in functional lung imaging protocols globally.
Ready To Discover Cyclopharm’s Global Expansion With Technegas?
Cyclopharm’s regulatory approval in Colombia marks its 67th country entry, reinforcing the company’s growing footprint in functional lung imaging and AI-enhanced respiratory diagnostics. This milestone aligns with the upcoming WFNMB Congress, offering a strategic platform for accelerated adoption and market engagement.
Explore detailed insights about Cyclopharm’s innovative projects and investment potential by visiting the Cyclopharm investor centre. Learn how the company’s proven market entry strategy is driving global growth and recurring revenue opportunities.